# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jaguar Supports Proof-Of-Concept Studies For Rare Disease Indications With Results Expected By End Of 2024 And 2025
Jaguar Health shares are trading lower by 15.4% during Tuesday's session. The company reported worse-than-expected second-q...
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(4.04) per share which missed the analyst consensus estimate of $(1.1...
Jaguar Health shares are falling Tuesday after the company announced its phase 3 OnTarget trial did not meet its primary endpoi...
-SEC